Mutual of America Capital Management LLC Trims Holdings in Vericel Co. (NASDAQ:VCEL)

Mutual of America Capital Management LLC lowered its holdings in Vericel Co. (NASDAQ:VCEL) by 2.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 132,219 shares of the biotechnology company’s stock after selling 2,780 shares during the period. Mutual of America Capital Management LLC’s holdings in Vericel were worth $5,586,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Geneva Capital Management LLC lifted its position in shares of Vericel by 61.4% in the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock worth $46,660,000 after purchasing an additional 420,078 shares during the period. Congress Asset Management Co. boosted its position in Vericel by 37.4% during the 3rd quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company’s stock valued at $54,575,000 after acquiring an additional 351,550 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Vericel by 34.9% during the 2nd quarter. Federated Hermes Inc. now owns 840,787 shares of the biotechnology company’s stock worth $38,575,000 after acquiring an additional 217,437 shares during the period. TimesSquare Capital Management LLC raised its position in shares of Vericel by 54.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company’s stock worth $24,934,000 after acquiring an additional 209,009 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Vericel by 51.5% in the 2nd quarter. Victory Capital Management Inc. now owns 611,146 shares of the biotechnology company’s stock valued at $28,039,000 after purchasing an additional 207,714 shares during the period.

Insider Activity

In other Vericel news, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now owns 220,937 shares of the company’s stock, valued at $9,142,373.06. The trade was a 7.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven C. Gilman sold 5,833 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the completion of the sale, the director now directly owns 11,000 shares of the company’s stock, valued at approximately $443,850. This trade represents a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,166 shares of company stock valued at $1,200,764 in the last 90 days. Company insiders own 7.20% of the company’s stock.

Vericel Stock Performance

VCEL stock opened at $55.83 on Wednesday. The company has a market cap of $2.76 billion, a price-to-earnings ratio of 930.66 and a beta of 1.66. The business’s 50-day moving average is $45.10 and its two-hundred day moving average is $46.74. Vericel Co. has a fifty-two week low of $32.31 and a fifty-two week high of $57.81.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. Equities analysts predict that Vericel Co. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. TD Cowen increased their price objective on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Vericel in a research note on Friday, November 8th. Canaccord Genuity Group assumed coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. Finally, Stephens increased their target price on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $58.14.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.